Article Text

Omalizumab for childhood asthma

Statistics from

Omalizumab is a humanised monoclonal antibody against immunoglobulin E (IgE). Several trials have attested to its effectiveness in the treatment of asthma. It has been postulated that because people who live in the inner city are more likely to have multiple and high allergen exposure and are more likely to show allergic sensitisation, they may be more likely to respond to anti-IgE treatment. Now a US trial (N Engl J Med 2011;364 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.